Obesity, also known as adiposity, is a condition in which unhealthy amount of fat deposition occurs in the body. Obesity is characterized by an increment of amount and size of fat cells in the body. The medical professionals measure waist circumference and body mass index for diagnosis of obesity and overweight. There are many complications associated with obesity such as high blood pressure, metabolic syndrome, atherosclerosis, diabetes, heart disease, cancer, high blood cholesterol, and sleep disorders. The risk factors associated with obesity include unhealthy lifestyle habits such as lack of physical activity, unhealthy eating, not enough sleep, and high amount of stress, age, and family history. Rhythm Pharmaceuticals, Inc. is in the process of developing setmelanotide as a melanocortin type 4 receptor agonist for the treatment of obesity. Vanderbilt University is in the process of developing exenatide as a glucagon like peptide I receptor agonist for the treatment of obesity. Some of the companies having the pipeline of obesity include Rhythm Pharmaceuticals, Inc., Novo Nordisk A/S, Novartis AG, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.